Routine

Stable COPD — maintenance (GOLD ABE groups; inhaler therapy)

stable-copd-maintenance · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Long-term pharmacological and non-pharmacological management of stable COPD — distinct from the acute COPD exacerbation entry. GOLD uses the ABE assessment (symptoms by mMRC/CAT + exacerbation history) to guide initial inhaler choice, with blood eosinophils informing ICS use. Goal: reduce symptoms and future exacerbation risk, preserve function.

Red flags

  • Frequent/severe exacerbations despite optimal inhaled therapy
  • Progressive breathlessness or falling FEV1
  • Resting hypoxaemia (consider LTOT assessment)
  • Weight loss / haemoptysis / new focal signs — exclude malignancy
  • Signs of cor pulmonale / right heart failure
  • Overlap with sleep-disordered breathing (daytime hypercapnia)

Assessment

Differential diagnosis

  • Asthma / asthma-COPD overlap
  • Bronchiectasis
  • Heart failure
  • Chronic pulmonary thromboembolic disease
  • Interstitial lung disease
  • Lung cancer
  • Alpha-1 antitrypsin deficiency (consider if young/non-smoker/basal emphysema)

Investigations

  • Post-bronchodilator spirometry (FEV1/FVC <0.70) — required to diagnose; GOLD grades 1-4 by FEV1% predicted
  • Symptom burden: mMRC dyspnoea scale and/or CAT score
  • Exacerbation history over past 12 months (number, hospitalisations) -> GOLD group A, B or E
  • Blood eosinophil count (guides ICS)
  • CXR; consider CT if suspicion of bronchiectasis/malignancy/emphysema distribution
  • Alpha-1 antitrypsin level once in all COPD (esp. young/non-smoker)
  • Pulse oximetry +/- ABG; assess for chronic hypoxaemia (consider LTOT if PaO2 <=7.3 kPa, or <=8.0 with cor pulmonale/polycythaemia)
  • Screen comorbidities: cardiovascular disease, osteoporosis, depression, anxiety; BMI/nutrition

Management

  • Confirm diagnosis with post-bronchodilator spirometry — do not treat 'COPD' without obstruction
  • Classify by GOLD group: A (low symptoms, 0-1 non-hospitalised exacerbation), B (more symptoms, 0-1 exacerbation), E (>=2 moderate or >=1 hospitalised exacerbation/yr)
  • Group A: one long-acting bronchodilator (LABA or LAMA)
  • Group B: LABA + LAMA dual bronchodilator (single inhaler preferred)
  • Group E: LABA + LAMA; add ICS (triple therapy) if blood eosinophils >=300 cells/microlitre
  • Non-pharmacological bundle is central: smoking cessation (most important), pulmonary rehabilitation, influenza + pneumococcal + COVID vaccination
  • Follow-up review of symptoms and exacerbations; escalate/de-escalate using the eosinophil-guided pathway
  • Assess LTOT, inhaler technique, and self-management/action plan at each review
  • Consider roflumilast or azithromycin in selected frequent exacerbators on triple therapy (specialist); lung volume reduction / transplant in advanced disease

Drugs & doses

Tiotropium 18 micrograms inhalation powder once daily (or 5 micrograms Respimat OD) — LAMA
Indacaterol/glycopyrronium or umeclidinium/vilanterol or similar LABA/LAMA once daily (single-inhaler dual bronchodilator) [verify local product]
Fluticasone furoate/umeclidinium/vilanterol (or budesonide/glycopyrronium/formoterol) once/twice daily — single-inhaler triple therapy where ICS indicated [verify local product]
Salbutamol 100-200 micrograms inhaled PRN as short-acting reliever
Roflumilast 500 micrograms PO once daily — selected severe COPD with chronic bronchitis and frequent exacerbations (specialist)
Azithromycin 250-500 mg PO three times weekly — long-term for frequent exacerbators (exclude NTM, baseline ECG/QTc; specialist) [verify local dose]

Disposition

Primary care / respiratory outpatient. Refer for pulmonary rehabilitation, LTOT assessment, or specialist review if frequent exacerbations, severe airflow limitation, suspected overlap, or candidacy for advanced therapies.

Complications & pitfalls

  • Recurrent exacerbations and hospitalisation
  • Chronic respiratory failure, cor pulmonale
  • Pneumonia (higher risk with ICS)
  • Secondary polycythaemia
  • Pneumothorax (bullous disease)
  • Osteoporosis, cachexia, depression, cardiovascular disease

Exam pearls

  • GOLD 2024/2025: initial therapy by ABE group — A single bronchodilator, B and E start LABA+LAMA; add ICS in group E when eosinophils >=300 (GOLD Report).
  • Avoid ICS monotherapy in COPD; ICS raises pneumonia risk — favour it in eosinophilic frequent-exacerbator phenotype, avoid with eos <100 or repeated pneumonia.
  • Smoking cessation and pulmonary rehabilitation are the only interventions (with LTOT and lung volume reduction in selected patients) shown to alter the natural history/mortality.
  • Note: the 2026 GOLD report lowered the threshold for group E to any >=1 moderate/severe exacerbation per year — verify against the current report in use locally.
  • Always check inhaler technique and adherence before escalating.
  • Triple therapy (LABA/LAMA/ICS) reduces exacerbations and mortality vs dual in the eosinophilic frequent-exacerbator group.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.